{
    "id": 21470,
    "fullName": "FGF19 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FGF19 positive indicates the presence of the FGF19 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9965,
        "geneSymbol": "FGF19",
        "terms": [
            "FGF19"
        ]
    },
    "variant": "positive",
    "createDate": "04/21/2016",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5910,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, U3-1784 inhibited growth of FGF19-positive hepatocellular carcinoma cell lines in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #3852).",
            "molecularProfile": {
                "id": 21999,
                "profileName": "FGF19 positive"
            },
            "therapy": {
                "id": 3980,
                "therapyName": "U3-1784",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5194,
                    "pubMedId": null,
                    "title": "U3-1784, a human anti-FGFR4 antibody for the treatment of cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=800c7dcf-322a-4e97-830b-0887c43f4108&cKey=4b473f86-5e89-431f-b228-b5a1a902ce34&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11975,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BLU-554 treatment resulted in tumor reduction in 58% (11/19, 1 complete response, 4 partial response, 6 stable disease) of Fgf19-positive hepatocellular carcinoma patients, but only in 15% (4/27, 4 stable disease) of Fgf19-negative patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 365O; NCT02508467).",
            "molecularProfile": {
                "id": 21999,
                "profileName": "FGF19 positive"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9941,
                    "pubMedId": null,
                    "title": "Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC)",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10802,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BLU-554 demonstrated safety and preliminary efficacy, resulting in radiographic partial response in 12.5% (1/8) and stable disease in 12.5% (1/8) of patients with hepatocellular carcinoma, and tumors in both responders were FGF19 positive (European Journal of Cancer, Dec 2016, Vol 69, Suppl 1, S41).",
            "molecularProfile": {
                "id": 21999,
                "profileName": "FGF19 positive"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8833,
                    "pubMedId": null,
                    "title": "First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation",
                    "url": "http://www.sciencedirect.com/science/article/pii/S0959804916327046?via%3Dihub"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19461,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) did not significantly inhibit tumor growth in a cell line xenograft model of FGF19, KLB, and FGFR4-positive hepatocellular carcinoma compared to FGF401 treatment (PMID: 31409633).",
            "molecularProfile": {
                "id": 34158,
                "profileName": "FGF19 pos FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19457,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF401 inhibited proliferation of FGF19, KLB, and FGFR4-positive hepatocellular carcinoma cell lines in culture, and inhibited tumor growth and induced tumor stasis and regression in cell line and patient-derived xenograft (PDX) models of hepatocellular carcinoma (PMID: 31409633).",
            "molecularProfile": {
                "id": 34158,
                "profileName": "FGF19 pos FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 2031,
                "therapyName": "FGF401",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20435,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cell lines expressing FGF19, FGFR4, and KLB demonstrated sensitivity to treatment with Fisogatinib (BLU-554) in culture (PMID: 31409633).",
            "molecularProfile": {
                "id": 34158,
                "profileName": "FGF19 pos FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20436,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cell lines expressing FGF19, FGFR4, and KLB demonstrated sensitivity to treatment with H3B-6527 in culture (PMID: 31409633).",
            "molecularProfile": {
                "id": 34158,
                "profileName": "FGF19 pos FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 6610,
                "therapyName": "H3B-6527",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19458,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF401 inhibited proliferation of a FGF19, KLB, and FGFR4-positive gastric cancer cell line in culture, and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 31409633).",
            "molecularProfile": {
                "id": 34158,
                "profileName": "FGF19 pos FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 2031,
                "therapyName": "FGF401",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19459,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF401 inhibited proliferation of a breast cancer cell line with expression of FGF19 and KLB and overexpression of FGFR4 in culture (PMID: 31409633).",
            "molecularProfile": {
                "id": 34159,
                "profileName": "FGF19 pos FGFR4 over exp KLB pos"
            },
            "therapy": {
                "id": 2031,
                "therapyName": "FGF401",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21999,
            "profileName": "FGF19 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34158,
            "profileName": "FGF19 pos FGFR4 pos KLB pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34159,
            "profileName": "FGF19 pos FGFR4 over exp KLB pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}